Group 1 - Company has received approval for a supplemental application for Everolimus tablets, adding a new 2.5mg specification to the existing 5mg specification [1][2] - The approved drug, Everolimus, is indicated for various conditions including advanced renal cell carcinoma and neuroendocrine tumors [2][3] - The company has invested approximately 740,420 RMB in the development of the 2.5mg specification of Everolimus [3] Group 2 - The company’s subsidiary has received approval for veterinary products, including Doxycycline tablets and a vaccine for swine fever, enhancing its product line in the veterinary sector [6][8] - Doxycycline is indicated for infections caused by various bacteria, while the swine fever vaccine has an immunity period of six months [7][8] - The approval of these veterinary products is expected to strengthen the company's market position in the veterinary medicine sector [10]

截至目前，公司通过公开渠道未能获得市场其他公司上述同类产品具体销售收入数据。 (一)盐酸多西环素片适用于革兰氏阳性菌、阴性菌和支原体等的感染。2025年9月13日，中华人民共和 国农业农村部受理了海正动保公司递交的盐酸多西环素片产品批准文号申请。盐酸多西环素片其他主要 生产厂家有河南中牧威锋生物工程有限公司、安徽康牧动物保健品有限公司等。 格隆汇12月23日丨海正药业(600267.SH)公布,近日，公司控股子公司海正动保公司、云南生物分别收到 中华人民共和国农业农村部核准签发的盐酸多西环素片、猪瘟病毒 E2 蛋白重组杆状病毒灭活疫苗(WH- 09 株)兽药产品批准文号批件。 2025年10月30日，中华人民共和国农业农村部受理了云南生物递交的猪瘟病毒E2蛋白重组杆状病毒灭 活疫苗(WH-09株)产品批准文号申请。云南生物是国内第4家获得该疫苗产品批准文号批件的企业，其 他主要生产厂家为山东海利生物制品有限公司、武汉科前生物股份有限公司和安徽东方帝维生物制品股 份有限公司。 (二)猪瘟病毒 E2 蛋白重组杆状病毒灭活疫苗(WH-09 株)适用于预防猪瘟，免疫期为6个月。 ...

Core Viewpoint - In 2024, Lianhuan Pharmaceutical experienced a decline in revenue and net profit, highlighting issues in operational efficiency and cost control despite advancements in R&D and market expansion [1][4][6] Group 1: Financial Performance - The company reported a total revenue of 2.16 billion yuan, a year-on-year decrease of 0.63% [1] - Net profit attributable to shareholders was 84 million yuan, down 37.66% year-on-year, while the non-recurring net profit fell by 56.89% to 49.87 million yuan [1][4] - Operating cash flow net amount was 1.08 million yuan, reflecting a significant decline of 93.3% year-on-year, indicating serious issues in cash flow management [6] Group 2: R&D Investment - R&D investment doubled to 277 million yuan, a year-on-year increase of 95.93%, with multiple new drug projects advancing in clinical trials [4] - Despite the increased investment, the lack of economic returns from innovation is evident, as the non-recurring net profit dropped significantly [4] Group 3: Market Expansion - The company achieved notable sales growth in key products, with sales of Aipulete tablets reaching 119 million pieces, up 30.28%, and Doxycycline hydrochloride tablets increasing by 47.89% to 71.47 million pieces [5] - However, the gross profit was only 1.07 billion yuan, a modest increase of 1.91%, indicating pressure on profit margins due to rising costs and intensified market competition [5]

特一药业集团股份有限公司 股票代码：002728 股票简称：特一药业 公告编号：2025-014 关于公司药品盐酸多西环素片通过一致性评价的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 三、对公司的影响 本次"盐酸多西环素片"仿制药质量和疗效一致性评价的通过，是公司研发能力、 生产及质量管理体系等综合实力的体现，也是国家药品监管部门对上述综合实力和产品 质量的认可；同时，也为公司后续品种通过仿制药质量和疗效一致性评价提供了重要的 宝贵经验借鉴。本次"盐酸多西环素片"通过仿制药质量和疗效一致性评价，对公司有 积极影响，有利于公司参与集采的投标，提升产品的市场竞争力，扩大产品的市场份额。 特一药业集团股份有限公司(以下简称"公司")于近日获得国家药品监督管理局核 准签发的"盐酸多西环素片"的《药品补充申请批准通知书》，经审查，上述药品通过 化学仿制药质量和疗效一致性评价。本次通过一致性评价的盐酸多西环素片共有 2 个规 格，分别为 0.05g、0.1g（其中 0.05g 规格为首家通过一致性评价，0.1g 规格为第二家 通过一致性评价），相关情况如下： | ...